Acadian Asset Management’s Karyopharm Therapeutics KPTI Stock Holding History

Acadian Asset Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.92M	Buy	298,997 +50,040	+20%	+$434K	﹤0.01%	961
2026 Q1	$1.38M	Buy	248,957 +245,231	+6,582%	+$1.87M	﹤0.01%	1069
2025 Q4	$27K	Buy	+3,726	New	+$22.8K	﹤0.01%	1872
2025 Q1	–	Sell	-22,856	Closed	-$230K	–	1720
2024 Q4	$230K	Sell	22,856 -1,711	-7%	-$20.7K	﹤0.01%	1239
2024 Q3	$304K	Buy	24,567 +11,622	+90%	+$144K	﹤0.01%	1225
2024 Q2	$167K	Buy	+12,945	New	+$214K	﹤0.01%	1460
2024 Q1	–	Sell	-18,337	Closed	-$237K	–	1683
2023 Q4	$237K	Buy	+18,337	New	+$247K	﹤0.01%	1206
2023 Q3	–	Sell	-6,596	Closed	-$177K	–	1747
2023 Q2	$177K	Buy	+6,596	New	+$284K	﹤0.01%	1296
2023 Q1	–	Sell	-56,383	Closed	-$2.87M	–	1854
2022 Q4	$2.87M	Sell	56,383 -322	-0.6%	-$22.3K	0.01%	586
2022 Q3	$4.64M	Buy	56,705 +44,352	+359%	+$3.31M	0.03%	417
2022 Q2	$836K	Sell	12,353 -20,908	-63%	-$1.92M	﹤0.01%	852
2022 Q1	$3.67M	Buy	+33,261	New	+$4.15M	0.02%	526
2019 Q2	–	Sell	-3,796	Closed	-$333K	–	1935
2019 Q1	$333K	Buy	+3,796	New	+$421K	﹤0.01%	1220
2017 Q2	–	Sell	-272	Closed	-$52K	–	1515
2017 Q1	$52K	Buy	+272	New	+$43.7K	﹤0.01%	1230

Other funds holding KPTI

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CCM

Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Acadian Asset Management's KPTI Position: Q2 2026 in Review

Acadian Asset Management increased its Karyopharm Therapeutics (KPTI) stake by 20% in Q2 2026, buying an estimated $434K and bringing the position to 298,997 shares worth $2.92M. The position accounts for ﹤0.01% of the portfolio, ranked #961.

Acadian Asset Management first reported a position in KPTI in Q1 2017 and has held it in 14 quarters since. The position peaked at $4.64M in Q3 2022. 97 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

Acadian Asset Management held 298,997 shares of Karyopharm Therapeutics worth $2.92M as of Q2 2026.
Acadian Asset Management bought 50,040 Karyopharm Therapeutics shares in Q2 2026, an estimated $434K.
Karyopharm Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #961 holding.
Acadian Asset Management first reported a position in Karyopharm Therapeutics in Q1 2017 and has held it in 14 quarters since.
Acadian Asset Management's Karyopharm Therapeutics position peaked at $4.64M in Q3 2022.
97 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.